Literature DB >> 28741375

Comparison of slow and forced vital capacities on ability to predict survival in ALS.

Susana Pinto1,2, Mamede de Carvalho1,3.   

Abstract

INTRODUCTION: Slow (SVC) and forced (FVC) vital capacities are the most used pulmonary function tests in amyotrophic lateral sclerosis (ALS). It is unknown if they equally predict survival in ALS. The aim of the present study was to compare both measures in predicting survival in this disease.
METHODS: Consecutive definite/probable ALS patients (2000-2014) in whom respiratory tests were performed at baseline and four months later were included. All patients were evaluated with the revised ALS functional rating scale (ALSFRS-R), respiratory (RofALSFRS-R), bulbar (ALSFRSb), upper and lower limb subscores, SVC, FVC, maximal inspiratory (MIP) and expiratory (MEP) pressures. King's functional staging system was applied retrospectively. Survival analysis was carried out by univariate Kaplan-Meier log-rank test. Multivariate Cox proportional hazards model determined significant independent variables.
RESULTS: We included 469 patients (270 males; mean onset age 61.0 ± 11.5 years; mean disease duration from first symptoms to first visit: 15.8 ± 16.1months; 329 spinal and 140 bulbar onset). FVC and SVC were strongly correlated (r2 = 0.981, p < 0.001). Significant survival prognostic variables (Kaplan-Meier analyses) were onset region, age, disease duration, ALSFRS-R, ALSFRSb, RofALSFRS-R, ALSFRS-R decay, SVC, FVC, MIP, MEP and King's staging (p ≤ 0.01). Final Cox model including the significant variables showed similar results for FVC and SVC (p < 0.001). Moreover, 1% decrease in either predicted values increased death probability by 1.02.
CONCLUSION: FVC and SVC are inter-changeable in predicting survival in ALS.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; forced vital capacity; slow vital capacity; survival

Mesh:

Year:  2017        PMID: 28741375     DOI: 10.1080/21678421.2017.1354995

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  7 in total

Review 1.  Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.

Authors:  Christina N Fournier
Journal:  Neurotherapeutics       Date:  2022-07-11       Impact factor: 6.088

2.  Comparison between breath stacking technique associated with expiratory muscle training and breath stacking technique in amyotrophic lateral sclerosis patients: Protocol for randomized single blind trial.

Authors:  Alessandra Dorça; Livia A Alcântara; Denise Sisterolli Diniz; Max Sarmet; Sérgio Ricardo Menezes Mateus; Luis Vicente Franco Oliveira; Hamilton Franco; Vinicius Maldaner
Journal:  Contemp Clin Trials Commun       Date:  2020-09-02

3.  A Prediction Model for Peak Expiratory Flow Derived From Venous Blood Biomarkers and Clinical Factors in Amyotrophic Lateral Sclerosis.

Authors:  Xianghua He; Jiaming Feng; Xue Cong; Hongyan Huang; Quanzhen Zhao; Qiuyan Shen; Fang Xu; Yanming Xu
Journal:  Front Public Health       Date:  2022-05-27

4.  A standard operating procedure for King's ALS clinical staging.

Authors:  Rubika Balendra; Ahmad Al Khleifat; Ton Fang; Ammar Al-Chalabi
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-02-18       Impact factor: 4.092

Review 5.  Diaphragmatic Neurophysiology and Respiratory Markers in ALS.

Authors:  Mamede de Carvalho; Michael Swash; Susana Pinto
Journal:  Front Neurol       Date:  2019-02-21       Impact factor: 4.003

6.  Peak expiratory flow is a reliably household pulmonary function parameter correlates with disease severity and survival of patients with amyotrophic lateral sclerosis.

Authors:  Qi-Jie Zhang; Jian-Chai Huang; Jia Chen; Wei Hu; Liu-Qing Xu; Qi-Fu Guo
Journal:  BMC Neurol       Date:  2022-03-19       Impact factor: 2.474

Review 7.  Optimal NIV Medicare Access Promotion: Patients With Thoracic Restrictive Disorders: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society.

Authors:  Lisa F Wolfe; Joshua O Benditt; Loutfi Aboussouan; Dean R Hess; John M Coleman
Journal:  Chest       Date:  2021-07-30       Impact factor: 9.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.